Deutsch Intern
Institute for Clinical Epidemiology and Biometry

COVIDOM

The COVIDOM study, also known as the Population-based Platform (POP), is part of the National Pandemic Cohort Network (NAPKON), which was established in July 2020 as part of the Network of University Medicine (NUM). NAPKON brings together previously decentralised national research activities into a common framework of cohorts and infrastructures. NAPKON aims to recruit a high quality cohort of patients with the coronavirus disease 2019 (COVID-19) for in-depth phenotyping of the disease.

Specifically, the COVIDOM study identified all patients with survived SARS-CoV-2 infection in geographically defined collection areas, regardless of severity and representative of the population, and invited them to participate in a long-term diagnostic programme. A detailed retrospective recording of the acute course of the disease and a prospective biomaterial collection as well as the recording of long-term sequelae and comorbidities are performed in an epidemiologically oriented focus hospital in the respective collection regions. The study has been successfully established at the three sites Charité Berlin, University Medical Centre Schleswig-Holstein (UKSH) on the Kiel campus and University Medical Centre Würzburg. Annual follow-up examinations (by telephone or on-site) are performed to monitor the long-term outcomes. The aim of the study is to retrospectively record the acute course of the disease and to prospectively investigate long-term organ damage and secondary morbidities after a SARS-CoV-2 infection in a population-representative approach across all degrees of disease severity. Inclusion criteria for the NAPKON-POP/COVIDOM study include: positive PCR test for SARS-CoV-2 at least 6 months prior to study inclusion, primary residence in one of the three study regions, minimum age 18 years. Recruitment has been completed. Follow-up examinations will be continued until the end of 2024.

Publications

Hartung T, Neumann C, Bahmer T, Chaplinskaya-Sobol I, Enders M, Geritz J, Haeusler KG, Heuschmann PU, Hildesheim H, Hinz A, Hopff S, Horn A, Krawczak M, Krist L, Kudelka J, Lieb W, Maetzler C, Mehnert-Theuerkauf A, Montellano F, Morbach C, Schmidt S, Schreiber S, Steigerwald F, Störk S, Maetzler W, Finke C:
Fatigue and cognitive impairment after COVID-19: A prospective multicenter study.
eClinicalMedicine, Volume 53, 2022, 101651. DOI: 10.1016/j.eclinm.2022.101651

Thomas Bahmer, Christoph Borzikowsky, Wolfgang Lieb, Anna Horn, Lilian Krist, Julia Fricke, Carmen Scheibenbogen, Klaus F. Rabe, Walter Maetzler, Corina Maetzler, Martin Laudien, Derk Frank, Sabrina Ballhausen, Anne Hermes, Olga Miljukov, Karl Georg Haeusler, Nour Eddine El Mokhtari, Martin Witzenrath, Jörg Janne Vehreschild, Dagmar Krefting, Daniel Pape, Felipe A. Montellano, Mirjam Kohls, Caroline Morbach, Stefan Störk, Jens-Peter Reese, Thomas Keil, Peter Heuschmann, Michael Krawczak, Stefan Schreiber.
Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study.
eClinicalMedicine. Vol. 52. 2022: 101549, DOI: https://doi.org/10.1016/j.eclinm.2022.101549

Horn A, Krist L, Lieb W, Montellano FA, Kohls M, Haas K, Gelbrich G, Bolay-Gehrig SJ, Morbach C, Reese JP, Störk S, Fricke J, Zoller T, Schmidt S, Triller P, Kretzler L, Rönnefarth M, Von Kalle C, Willich SN, Kurth F, Steinbeis F, Witzenrath M, Bahmer T, Hermes A, Krawczak M, Reinke L, Maetzler C, Franzenburg J, Enderle J, Flinspach A, Vehreschild J, Schons M, Illig T, Anton G, Ungethüm K, Finkenberg BC, Gehrig MT, Savaskan N, Heuschmann PU, Keil T, Schreiber S.
Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP).

Hartung TJ, Bahmer T, Chaplinskaya-Sobol I, Deckert J, Endres M, Franzpötter K, et al. Predictors of non-recovery from fatigue and cognitive deficits after COVID-19: a prospective, longitudinal, population-based study. eClinicalMedicine [Internet]. 2024;69:102456. Available from: https://www.sciencedirect.com/science/article/pii/S258953702400035X

Shi Y, Strobl R, Apfelbacher C, Bahmer T, Geisler R, Heuschmann P, et al. Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort. Infection. 2023;:1-16.